Search...
BIIB: Felzartamab and lupus assets advance in late-stage trials, targeting major unmet needs
I'm PortAI, I can summarize articles.
Biogen (BIIB) is advancing its immunology pipeline with felzartamab showing strong efficacy in late AMR and potential for durable disease control in IgA nephropathy and PMN. The company also has multiple phase 3 and proof-of-concept studies underway, and its lupus programs are progressing with differentiated mechanisms and endpoints. This information is based on an AI-generated summary of Biogen's Piper Sandler 37th Annual Healthcare Conference Audio Transcript from December 3, 2025.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments